MicroRNA-543 inhibits the proliferation, migration, invasion, and epithelial-mesenchymal transition of triple-negative breast cancer cells via down-regulation of ACTL6A gene

PurposeTo investigate the effect of microRNA-543 (miR-543) on the proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of triple-negative breast cancer (TNBC) cells, and the associated mechanism.MethodsHuman breast cancer cells (MDA-MB-231, HCC1937, and MCF-7, ZR-75–1) and normal human breast epithelial cell line (MCF10A) were transfected with miR-543 mimics or inhibitor using lipofectamine 2000. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting were used to determine the mRNA and protein expression levels of miR-543, actin-like protein 6A (ACTL6A), vimentin, Snail, and E-cadherin in breast cancer cells/tissue. Cell counting kit-8 (CCK-8), wound-healing, and Transwell assays were used to measure the effect of miR-543 on TNBC cell proliferation, invasion, and migration. Overall survival was determined using data from Gene Expression Omnibus (GEO) and Cancer Genome Atlas (TCGA) databases. Bioinformatics analysis and luciferase reporter gene assay were used to determine the regulatory effect of miR-543 on ACTL6A.ResultsThe level of expression of miR-543 was significantly lower in breast cancer cells/tissue than in normal human breast epithelial cell/tissue (p < 0.05). MicroRNA-543 expression level was significantly reduced in TNBC cells/tissue, relative to the other breast cancer cells/normal breast tissue (p < 0.05). MicroRNA-543 significantly suppressed tumor growth and the proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) of TNBC cells, in mouse xenograft model (p < 0.05).

Cáncer colorrectal familiar y hereditario / Hereditary and familial colorectal cancer

Hasta un 5% de todos los casos de cáncer colorrectal se deben a un síndrome hereditario conocido. Estas formas hereditarias demandan en muchas ocasiones un alto grado de sospecha para su diagnóstico y requieren de un manejo específico y especializado. Además, el diagnóstico del cáncer colorrectal hereditario tiene importantes consecuencias no solo para el paciente, para el que existen medidas de prevención altamente efectivas, sino también para los familiares, que pueden ser portadores de la misma condición. Los avances más significativos en el campo del cáncer colorrectal hereditario se han producido en el diagnóstico y caracterización de estos síndromes

Up to 5% of all colorectal cancer cases are caused by a known hereditary syndrome. These hereditary types often need a higher degree of clinical suspicion to be diagnosed and require specific and specialized management. In addition, diagnosing hereditary colorectal cancer has significant consequences not only for the patient, for whom there are effective preventative measures, but also for their families, who could be carriers of the condition. The most significant advances in the field of colorectal cancer have come from the diagnosis and characterization of these syndromes